P. Chinet-Charrot

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial

Karim Fizazi, Laura Faivre, F. Lesaunier et al. · The Lancet Oncology · 2015 · 238 citations

Medicine, Oncology, Urology +17

Interstitial brachytherapy for penile carcinoma: a multicentric survey (259 patients)

R Rozan, Éliane Albuisson, B Giraud et al. · Radiotherapy and Oncology · 1995 · 117 citations

Medicine, Oncology, Urology +12

Non-Hodgkin’s lymphoma of the testis: A retrospective study of 84 patients treated in the French anticancer centres

J.L. Lagrange, A. Ramaioli, C Théodore et al. · Annals of Oncology · 2001 · 74 citations · Full text

Medicine, Oncology, Surgery +11

A phase III trial of docetaxel–estramustine in high-risk localised prostate cancer: A planned analysis of response, toxicity and quality of life in the GETUG 12 trial

Karim Fizazi, F. Lesaunier, R. Delva et al. · European Journal of Cancer · 2011 · 53 citations · Full text

Medicine, Oncology, Pharmacology +14

Do Patients With Advanced Urothelial Carcinoma Benefit From Weekly Paclitaxel Chemotherapy? A GETUG Phase II Study

Florence Joly, Nadine Houédé, Sabine Noal et al. · Clinical Genitourinary Cancer · 2009 · 50 citations

Medicine, Oncology, Pharmacology +8